TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
Nicholas Jacobus
Advertisement
Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.
Articles by Nicholas Jacobus
The drug is currently in Phase 1 clinical trials for gastric cancer treatments.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Serious is the Biosimilar Void?
2
Travere Therapeutics’ Filspari Receives Full FDA Approval
3
New Study Reveals Genetic Predictors for GLP-1 Weight Loss and Side Effects
4
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
5